19 Vestry Street
New York, NY 10013
United States
https://brightmindsbio.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Ian McDonald | Co-Founder, CEO, President & Director | S.O. | S.O. | 1989 |
Mr. Ryan E. S. K. Cheung B.Com., CA, CPA | Chief Financial Officer | 88,25k | S.O. | 1978 |
Dr. Jan Torleif Pedersen M.Sc., Ph.D. | Chief Science Officer & Director | 179,1k | S.O. | 1965 |
Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 240,87k | S.O. | 1955 |
Dr. Emer Leahy M.B.A., Ph.D. | Consultant | S.O. | S.O. | 1967 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
L’ISS Governance QualityScore de Bright Minds Biosciences Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..